[A21-130] Concept for routine practice data collection - autologous anti-CD19-transduced CD3+ cells

Last updated 17.11.2023

Project no.:
A21-130

Commission:
Commission awarded on 07.10.2021 by the Federal Joint Committee (G-BA).

Report type:
Rapid report

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Note:

Routine practice data collection (RPDC concept):

In the case of new drugs that have entered the health care system via a special marketing authorization or as a drug for the treatment of a rare disease, the study data at the time of marketing authorization are usually not very informative for the early benefit assessment. In these cases, according to the Law for More Safety in the Supply of Medicines (GSAV), the G-BA can require the pharmaceutical company to collect routine practice data, including the associated analysis, for the benefit assessment. IQWiG prepares the concept for such a routine practice data collection on behalf of the G-BA.

Federal Joint Committee (G-BA)

2023-11-16 A G-BA decision was published.
G-BA documents on this decision (German version)

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form